# Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

> **NCT03166215** · PHASE1,PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 18 (actual)

## Conditions studied

- Developmental and/or Epileptic Encephalopathies

## Interventions

- **DRUG:** TAK-935
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03166215
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2018-09-19
- **Final completion:** 2018-09-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166215, "Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03166215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*